Senzime Secures Major TetraGraph Order from Leading UK NHS Hospital System

Rhea-AI Summary

Senzime (OTCQX:SNZZF) announced an order for 70 TetraGraph systems from a leading UK NHS hospital trust to standardize neuromuscular monitoring across major operating rooms. The contract, secured via partner Healthcare 21, targets full implementation annual usage of more than 15,000 TetraSens sensors. Management called this its largest TetraGraph order in Europe and highlighted UK guidelines from the Association of Anaesthetists recommending quantitative monitoring in every operating theatre whenever neuromuscular blocking drugs are used. The TetraGraph system is used globally to support timing of intubation, individualized dosing, reversal decisions, and safe tracheal extubation.

Positive

• 70 TetraGraph systems ordered by a major UK NHS trust
• Expected annual usage of 15,000+ TetraSens sensors at full implementation
• Described as Senzime's largest TetraGraph order in Europe

Negative

• None.

UPPSALA, SE / ACCESS Newswire / December 9, 2025 / Senzime (STO:SEZI)(OTCQX:SNZZF) - Senzime AB (publ.) today announced that one of the leading NHS hospital trusts in the United Kingdom (UK) has ordered a total of 70 TetraGraph systems to standardize neuromuscular monitoring across all major operating rooms. The contract was secured by Senzime's partner in the UK, Healthcare 21, and annual usage is expected to exceed 15,000 TetraSens sensors at full implementation.

The National Health Service (NHS) is the publicly funded healthcare system in the UK. It is divided into more than 200 NHS trusts, including over 1,000 hospitals and approximately 3,000 operating rooms.

"This is a strategic win for us in the UK market and a clear signal that the NHS is accelerating the transition to the latest advancements in neuromuscular monitoring. It's our single largest TetraGraph order received to date in Europe, serving as an excellent reference for broader expansion. As UK guidelines strongly mandate the use of quantitative monitoring, we see significant momentum ahead and are proud to support safer anesthesia care for patients across the country", said Philip Siberg, CEO of Senzime.

The guidelines issued by the Association of Anaesthetists of Great Britain and Ireland (AAGBI) state that quantitative monitoring is essential and should be available in every operating theatre across the UK and Ireland. The guidelines further recommend using quantitative monitoring whenever neuromuscular blocking (NMB) drugs are administered, throughout all phases of anesthesia - from initiation of neuromuscular blockade until full recovery.

Senzime's TetraGraph system is used in thousands of operating rooms at university, public, private, military and veterans' hospitals worldwide to enhance patient safety before, during and after surgery. By accurately monitoring neuromuscular function in real time, TetraGraph supports safe timing of intubation, individualized dosing of paralytic and reversal agents, and proper timing of tracheal extubation, ensuring safe return to spontaneous breathing after surgery.

For further information, please contact:

Philip Siberg, CEO of Senzime AB
Phone: +46 (0) 707 90 67 34, e-mail: philip.siberg@senzime.com

Slavoljub Grujicic, CFO
Phone: +46 (0) 76 306 60 11, e-mail: slavoljub.grujicic@senzime.com

About Senzime

Senzime is a leading medical device company at the forefront of a changing healthcare market, driven by new clinical guidelines and emerging technologies. Established in 1999, Senzime develops and markets precision-based monitoring systems that improve outcomes, reduce costs, and advance perioperative patient safety. The flagship solution is the TetraGraph® system, proven best-in-class for accurate monitoring of neuromuscular transmission during surgery and used in thousands of operating rooms across the globe. The system helps to secure precise dosing of paralytic drugs and provides enhanced insights to safeguard every patient's journey, from anesthesia to recovery.

Headquartered in Uppsala, Sweden, Senzime is publicly traded on the Nasdaq Stockholm Main Market (SEZI), with cross-trading on the US OTCQX Market (SNZZF), and backed by long-term investors. More information is available at senzime.com.

Attachments

Senzime secures major TetraGraph order from leading UK NHS hospital system

SOURCE: Senzime

View the original press release on ACCESS Newswire

FAQ

What did Senzime (SNZZF) announce on December 9, 2025 regarding NHS orders?

Senzime announced a 70-unit TetraGraph order from a leading UK NHS hospital trust with expected >15,000 annual TetraSens sensors at full implementation.

How many TetraGraph systems did the NHS trust order from Senzime (SNZZF)?

The trust ordered 70 TetraGraph systems to standardize monitoring across major operating rooms.

What is the expected annual sensor usage tied to the Senzime (SNZZF) NHS order?

Annual usage is expected to exceed 15,000 TetraSens sensors at full implementation.

Who secured the Senzime (SNZZF) NHS contract in the UK?

The contract was secured by Senzime's UK partner, Healthcare 21.

Why is the NHS order strategically important for Senzime (SNZZF)?

Management called it the company's largest TetraGraph order in Europe and a reference for broader UK expansion.

How do UK guidelines affect demand for Senzime (SNZZF) TetraGraph systems?

AAGBI guidelines recommend quantitative neuromuscular monitoring in every operating theatre and when NMB drugs are used, supporting adoption of TetraGraph.